Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for Migraine Prevention in Chinese Participants
NCT05810038Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing DBT Rimegepant/OLE Rimegepant with DBT Placebo/OLE Rimegepant (2 arms). Primary endpoint: Mean Change in Number of Migraine Days Per Month at 12 weeks. Started May 2023; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05810038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810038.